Enlivex Ltd.
IPOEnlivex | Quality Longevity & Prediction Markets Treasury
Public · Ness Ziona, Israel · Founded 2005 · $220.0M raised
- Headquarters
- Ness Ziona
- Employees
- 11–50
- Founded
- 2005
- Business Model
- B2B
- Website
- enlivex.com
- Total Funding
- $220.0M
- Last Round
- $8.0M Series B
- Rounds
- 2
- Type
- Public
About
Enlivex is a Nasdaq-listed clinical-stage immunotherapy company developing Allocetra™, an off-the-shelf macrophage reprogramming cell therapy targeting inflammatory diseases including age-related knee osteoarthritis. Phase II data demonstrated 72% pain reduction and 109% functional improvement across over 250 patients, addressing a market valued at over $314 billion.
Summary
Enlivex Ltd. is a Biotech company based in Ness Ziona, Israel, founded in 2005. It has raised $220.0M in total across 2 rounds. Investors include KIP Global Pharma Private Equity Fund.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2019
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.